Pharmacokinetics of Bay k 4999, a new broad-spectrum penicillin.

Antimicrobial Agents and Chemotherapy
R WiseD P Thornhill

Abstract

The pharmacokinetics of the broad-spectrum penicillin Bay k 4999 were studied in six healthy male volunteers. A 2-g dose was given by the intravenous route. The tissue penetration of the antibiotic was studied by both dermabrasion and blister techniques. A total of 26.4% of the drug was recovered in the urine in 24 h, 79% of this being excreted in the first 2 h. The elimination half-life in serum was 1.3 h. The dermabrasion levels of Bay k 4999 were generally similar to those in serum, but after 1 h the blister fluid levels of antibiotic were greater than those in serum. Different drug levels obtained by blister and dermabrasion techniques may be due to the different composition of the two fluids.

References

May 1, 1977·Antimicrobial Agents and Chemotherapy·D Stewart, G P Bodey
May 1, 1978·The Journal of Antimicrobial Chemotherapy·M A EvansJ D Williams
Jan 1, 1977·Antimicrobial Agents and Chemotherapy·G P Bodey, T Pan
Apr 1, 1974·Journal of Pharmacokinetics and Biopharmaceutics·H G BoxenbaumR M Elashoff
Dec 21, 1973·Deutsche medizinische Wochenschrift·C SimonW Toeller
Oct 1, 1971·Journal of Clinical Pathology·J A Raeburn
Jul 8, 1967·British Medical Journal·E T KnudsenR Sutherland

❮ Previous
Next ❯

Citations

Aug 1, 1980·Antimicrobial Agents and Chemotherapy·M SeddonR Livingston

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.